February 27, 2015 8:06 PM ET

Biotechnology

Company Overview of Xencor, Inc.

Company Overview

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through its proprietary XmAb technology platform. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor under Phase Ib clinical trial initiation to treat asthma and allergic diseases; and XmAb5574/MOR208...

111 West Lemon Avenue

Monrovia, CA 91016

United States

Founded in 1997

37 Employees

Phone:

626-305-5900

Fax:

626-305-0350

Key Executives for Xencor, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 44
Total Annual Compensation: $363.7K
Chief Medical Officer
Age: 60
Total Annual Compensation: $322.5K
Chief Business Officer
Age: 55
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2013.

Xencor, Inc. Key Developments

Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Xencor, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $1,350,000 compared to $3,703,000 a year ago. Revenues were $5,664,000 against $1,745,000 a year ago. Loss from operations was $1,350,000 against $3,710,000 a year ago. For the year, the company reported net loss of $16,422,000 compared to $60,259,000 a year ago. Fully diluted net loss per share was $0.52 compared to $3.85 a year ago. Revenues were $9,520,000 against $10,172,000 a year ago. Loss from operations was $16,457,000 against $10,520,000 a year ago.

Xencor, Inc. to Report Q4, 2014 Results on Feb 19, 2015

Xencor, Inc. announced that they will report Q4, 2014 results on Feb 19, 2015

Xencor, Inc., Q4 2014 Earnings Call, Feb 19, 2015

Xencor, Inc., Q4 2014 Earnings Call, Feb 19, 2015

Similar Private Companies By Industry

Company Name Region
ICx Biosystems United States
Symbiomix Therapeutics LLC United States
Heartland Plant Innovations Inc. United States
Glycobia, Inc. United States
ConverGene LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Xencor, Inc., please visit www.xencor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.